Category Archives: Guangdong

Guangdong Launches Province‑Wide Survey on “Three Entry” Channels for Centralized Drug Procurement – Questionnaire Open to Primary, Private and Retail Healthcare Outlets Until 30 Sep 2026

Policy Milestone

Item	Detail
Issuing Authority	Guangdong Provincial Drug Trading Center
Policy Basis	Notice of the Guangdong Provincial Healthcare Security Administration on Promoting the Entry of Centrally Procured Drugs into Grassroots Medical Institutions, Private Medical Institutions and Retail Pharmacies (Yue Yi Bao Han [2025] No. 208)
Initiative	“Three Entry” (三进) program — bringing volume‑based procurement (VBP) drugs to grassroots, private and retail channels
Notice Date	4 Sep 2026
Submission Deadline	30 Sep 2026
Filing Method	Online questionnaire via QR code in the announcement — completed by the institution head or procurement lead
Support Channels	Hotline 020‑38302291; WeChat 19102021272 (weekdays 8:30–12:00, 14:00–17:30)

Survey Scope & Coverage

Public Grassroots Institutions: Township health centers, eligible community health service centers/stations, village clinics, and comparable primary‑care providers legally established and in normal operation within Guangdong.
Private Medical Institutions: Facilities designated under the medical‑insurance system.
Retail Pharmacies: Medical‑insurance‑designated drugstores, including both standalone and chain pharmacies.
Data Collected: Current procurement practices, procurement demand forecasts, existing procurement relationships, and financial‑service needs across all three channels.

Participation & Data Use

Filing Obligation: Institutions are asked to complete the Guangdong Province Centralized Drug Procurement “Three Entry” Project Questionnaire truthfully and accurately, reflecting actual operating conditions.
Purpose Limitation: Submitted information will be used only to optimize the provincial platform’s implementation plan for the “Three Entry” program, improve the procurement and supply‑chain service system, and deliver precision matchmaking services between channels and suppliers.
Deadline Discipline: The questionnaire closes on 30 Sep 2026; no extensions were mentioned in the notice.

Market Impact & Outlook

Extending VBP Beyond Public Hospitals: The “Three Entry” program pushes centrally procured, price‑compressed drugs down into primary care, private clinics, and retail pharmacies — significantly widening the reachable market for winning bidders in national and Guangdong provincial procurement rounds.
Data‑Driven Rollout: By first mapping demand forecasts and supply relationships channel‑by‑channel, Guangdong is signaling a precision‑implementation approach rather than a blanket mandate — survey results will likely shape distribution rules, platform workflows, and possibly channel‑specific financing support.
Strategic Signal for Suppliers and Distributors: Pharmaceutical manufacturers and distributors should treat the 30 Sep deadline as an early‑warning indicator: institutions that participate will be better positioned in subsequent matchmaking, and the survey footprint previews where VBP drug flow will be steered next.
Retail Channel Watch: Inclusion of chain and standalone pharmacies aligns with the national healthcare‑security agenda of routing VBP savings to outpatient and OTC‑adjacent settings — a structural shift for retail drug pricing in China’s largest provincial pharmaceutical market.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation timeline, survey outcomes, and channel‑expansion plans of Guangdong’s “Three Entry” program for centrally procured drugs. Actual results may differ due to risks including participation rates, subsequent policy directives from provincial healthcare‑security authorities, supply‑chain capacity, and platform execution.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2096765545348075520

Shenzhen Launches Three‑Year AI Action Plan Targeting ¥300 Billion Core Industry by 2028 – 23 Key Tasks to Fuse AI with Research, Industry, Consumption and City Governance

Policy Snapshot

Item	Detail
Issuing Authority	Shenzhen Municipal People’s Government
Policy	Shenzhen Action Plan for Promoting the Development of AI and Applications (2026–2028)
Time Horizon	2026–2028
Core Industry Target	AI core industry scale exceeding ¥300 billion by 2028
Enterprise Target	More than 3,000 AI companies
Adoption Target	>90% penetration of next‑generation smart terminals and AI agents
Task Framework	23 key tasks across six priority areas
Strategic Goal	Build Shenzhen into an “AI Pioneer City”

Six Priority Areas

Scientific Research: Shenzhen will build a “model–data–experiment” trinity technology system for scientific discovery, developing AI‑for‑Science foundation models on innovation platforms including Guangming Science City and Xili Lake International Science & Education City, and accelerating AI applications in biopharmaceuticals, high‑performance materials, and quantum technology.
Industrial Empowerment: AI will be embedded across the full advanced‑manufacturing value chain, with a push for industrial AI agents. The plan also drives AI convergence with professional services — finance, software, human resources, law, and accounting — expanding scenarios such as intelligent risk control, AI‑powered investment research, and AI coding.
AI‑Native Consumption: The city will foster “AI‑native” consumption, supporting AI phones, AI PCs, AI glasses, and humanoid robots, and exploring new formats such as digital avatars and AI emotional companionship. In culture and tourism, it backs intelligent NPCs, dynamic storylines, and AI comic dramas; in transport and logistics, it will expand last‑mile delivery by autonomous vehicles and drones across communities, business districts, and campuses.
People’s Livelihood: AI will empower employment, education, healthcare, elderly care, childcare, and housing. Shenzhen will continue to optimize its “Shen Xiaowei” health agent — offering smart triage, pre‑consultation intake, and medical report interpretation — and explore embodied‑intelligence devices for elder companionship and childcare supervision.
Urban Governance: Deep AI integration into city governance is listed among the six priority areas; specific measures were not detailed in the release.
Global Cooperation: Leveraging the Qianhai and Hetao platforms, Shenzhen will deepen international collaboration and refine the “Hong Kong R&D + Shenzhen Commercialization” model. Seizing the opportunity of the 33rd APEC Economic Leaders’ Informal Meeting, the city will showcase its AI solutions and push the “China AI stack” to go global, prioritizing Latin America, Southeast Asia, and Central Asia.

Foundation & Support Measures

Compute Infrastructure: Accelerate construction of flagship projects including Pengcheng Cloud Brain III.
Seven Pillars: Strengthen foundational capabilities in computing power, models, data, scenarios, talent, research platforms, and industrial funds.
Commercialization Pipeline: Move AI innovations from the laboratory to industry and urban applications at speed.

Market Impact & Outlook

National AI Race: The plan positions Shenzhen among China’s most aggressive municipal AI strategies, pairing a hard ¥300 billion core‑industry target with a 90% adoption benchmark that emphasizes real‑world deployment over pure research output.
Hardware Ecosystem Edge: Shenzhen’s consumer‑electronics supply chain — spanning AI phones, AI PCs, smart glasses, and humanoid robotics — gives it a structural advantage in monetizing the next wave of intelligent terminals.
Cross‑Border Innovation Model: The “Hong Kong R&D + Shenzhen Commercialization” pipeline, anchored by Qianhai and Hetao, offers a differentiated route for basic‑research translation under the Greater Bay Area framework.
Export Ambition: Targeting Latin America, Southeast Asia, and Central Asia, the plan signals a shift from exporting AI hardware to exporting full‑stack AI systems and governance solutions, with the APEC summit as a showcase moment.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding policy implementation timelines, industry scale targets, adoption rates, and commercialization expectations under Shenzhen’s AI Action Plan (2026–2028). Actual outcomes may differ due to risks including execution pace, technology maturation, funding availability, and the evolving global AI regulatory and competitive landscape.-China Health Reform Pulse

Policy Source: https://www.gd.gov.cn/zwgk/zcjd/snzcsd/content/post_4951847.html

Guangzhou Medical Insurance Separate Payment Policy Targets Hypertension Outpatient Care

Leave a reply

Guangzhou, Sept 1, 2026 — Guangzhou implemented an updated medical insurance separate payment policy, refining how nationally negotiated drugs are reimbursed for Category I outpatient-specific diseases such as hypertension while maintaining existing rules for general outpatient care and Category II disease clinics.

Policy Snapshot

Attribute	Detail
Effective date	Sept 1, 2026
Location	Guangzhou, Guangdong Province
Policy name	Improved Medical Insurance Separate Payment Management Policy
Scope	Nationally negotiated drugs (including agreement-period and converted catalog drugs; bid-winning drugs)
Key change	Category I outpatient-specific diseases (e.g., hypertension) now require a designated separate payment institution
Unchanged	General outpatient care and Category II outpatient-specific disease separate payment rules

How Separate Payment Works

Under the separate payment mechanism, costs for nationally negotiated drugs are not counted toward general outpatient or outpatient-specific disease benefit caps. Instead, the basic medical insurance pooled fund settles these costs separately with designated medical institutions, bypassing standard reimbursement limits.

Patient Access Pathways

Pathway 1 (General & Category II): Insured patients visiting their selected general outpatient institutions, specialized designated hospitals, or Category II outpatient-specific disease institutions can obtain separate payment drug prescriptions without changes to existing reimbursement rules.
Pathway 2 (Category I): Insured patients with Category I outpatient-specific disease benefits must select one designated separate payment institution for each condition. Prescriptions for separate payment drugs issued at the selected facility qualify for the separate payment benefit. Patients who fail to register a separate payment designation or visit non-selected institutions cannot access the separate payment benefit and must claim reimbursement under original Category I disease caps.

Hypertension Adjustment Example

Under the new rules, a hypertension patient previously able to obtain specialty drugs at both Hospital A and Hospital B must now designate only one facility as their hypertension separate payment institution. At the selected hospital, hypertension drugs qualify for separate payment—reimbursed at inpatient rates without counting toward the hypertension benefit cap. At non-selected hospitals, the same drugs are reimbursed at standard outpatient-specific disease rates and count toward the annual cap.

Market Impact Analysis

The policy tightens patient routing controls for high-cost nationally negotiated drugs used in chronic disease management, steering hypertension and other Category I patients toward single-institution loyalty. By requiring a designated separate payment facility, regulators are creating a closed-loop system that simplifies fund settlement for insurers while concentrating prescription volume at selected hospitals.

For pharmaceutical manufacturers, the change means drug uptake for hypertension therapies on the national negotiation list will increasingly depend on whether hospitals secure separate payment designation status and successfully attract patient registrations. Hospitals with strong primary care networks and chronic disease management programs are positioned to capture patient volume, while smaller facilities may see negotiated drug prescriptions migrate to competitors.

The inpatient-level reimbursement rate for separate payment drugs removes the financial ceiling that previously constrained long-term hypertension therapy adherence, potentially improving patient persistence on premium antihypertensive agents. However, the single-institution restriction limits patient choice and may reduce competitive pricing pressure between hospitals for chronic disease drug dispensing.

Forward-Looking Statement

Healthcare analysts expect Guangzhou’s separate payment model to be monitored closely by other tier-one cities as a template for managing nationally negotiated drug costs within outpatient chronic disease frameworks. If the single-institution designation proves effective in controlling fund leakage and improving settlement efficiency, similar restrictions could roll out across the Pearl River Delta by mid-2027. Pharmaceutical companies with hypertension and diabetes assets on the national negotiation list should prioritize partnerships with hospitals likely to secure high patient registration volumes under the new designation system.-China Health Reform Pulse

Policy Source: https://www.gd.gov.cn/zwgk/zdlyxxgkzl/ylws/content/post_4950117.html